ERBB2 and breast carcinoma: It was unknown whether the use of Oncotype DX test in women with HR+, HER2− breast cancer and 1–3 nodes positive treated by the UK National Health Service (NHS) would lead to a reduction in use of chemotherapy and whether it would increase or decrease confidence in the use or avoidance of chemotherapy for oncologists and patients.